Literature DB >> 19384232

The effects of neostigmine and glycopyrrolate on skin conductance as a measure of pain.

Thomas Ledowski1, James Preuss, Stephan A Schug.   

Abstract

BACKGROUND AND
OBJECTIVE: The number of fluctuations in skin conductance per second has been shown to correlate with postoperative pain. In this context, the effects of cholinesterase inhibitors and anticholinergic drugs used for the reversal of muscle relaxants were investigated.
METHODS: Muscle relaxant effects were reversed in 30 patients with neostigmine and glycopyrrolate. No reversal agents were given to 30 controls. Patients' level of pain was quantified using a numeric rating scale (0-10) at several time points in the recovery room. The number of fluctuations in skin conductance per second was measured simultaneously.
RESULTS: The number of fluctuations in skin conductance per second was significantly higher in patients with no and severe pain in the control compared with the reversal group (no pain 0.19 vs. 0.12; severe pain 0.40 vs. 0.19). The number of fluctuations in skin conductance per second was less sensitive to identify time points with moderate/severe pain in the reversal group.
CONCLUSION: Skin conductance-based assessment of pain is affected by reversal agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19384232     DOI: 10.1097/EJA.0b013e32832bb678

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  2 in total

1.  Skin conductance for monitoring of acute pain in adult postoperative patients: influence of electrode surface area and sampling time.

Authors:  Thomas Ledowski; Sebastian Albus; Jessica Stein; Bradley Macdonald
Journal:  J Clin Monit Comput       Date:  2011-10-26       Impact factor: 2.502

2.  Acute pain therapy in postanesthesia care unit directed by skin conductance: a randomized controlled trial.

Authors:  Michael Czaplik; Christa Hübner; Markus Köny; Julia Kaliciak; Fatima Kezze; Steffen Leonhardt; Rolf Rossaint
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.